US Stock MarketDetailed Quotes
KYTX Kyverna Therapeutics
- 13.230
- +0.230+1.77%
Close May 28 16:00 ET
- 13.230
- 0.0000.00%
Post 16:00 ET
570.41MMarket Cap-7512P/E (TTM)
13.720High12.820Low404.36KVolume13.200Open13.000Pre Close5.31MTurnover2.43%Turnover RatioLossP/E (Static)43.12MShares35.06052wk High1.58P/B220.61MFloat Cap12.15052wk Low--Dividend TTM16.68MShs Float35.060Historical High--Div YieldTTM6.92%Amplitude12.150Historical Low13.125Avg Price1Lot Size
Kyverna Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (FY)Dec 31, 2021 | |
|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 24.20%7.03M | 282K | 5.66M |
| Operating revenue | --0 | --0 | --0 | --0 | 24.20%7.03M | --282K | --5.66M |
| Cost of revenue | |||||||
| Gross profit | |||||||
| Operating expense | 156.51%29.36M | 71.40%62.41M | 136.03%21.38M | 11.45M | 13.77%36.41M | 9.06M | 32M |
| Selling and administrative expenses | 151.72%6.88M | 55.90%12.48M | 111.76%4.21M | --2.73M | 30.20%8.01M | --1.99M | --6.15M |
| -General and administrative expense | 151.72%6.88M | 55.90%12.48M | 111.76%4.21M | --2.73M | 30.20%8.01M | --1.99M | --6.15M |
| Research and development costs | 158.02%22.48M | 75.77%49.92M | 142.86%17.16M | --8.71M | 9.86%28.4M | --7.07M | --25.85M |
| Operating profit | -156.51%-29.36M | -112.38%-62.41M | -143.61%-21.38M | -11.45M | -11.53%-29.38M | -8.78M | -26.35M |
| Net non-operating interest income expense | 782.30%2.69M | 319.00%2.1M | 189.84%742K | 305K | 25,100.00%500K | 256K | -2K |
| Non-operating interest income | 683.67%2.74M | 303.89%2.28M | 165.66%789K | --349K | 56,400.00%565K | --297K | --1K |
| Non-operating interest expense | 0.00%44K | 187.69%187K | 14.63%47K | --44K | 2,066.67%65K | --41K | --3K |
| Other net income (expense) | -766.67%-26K | -511.11%-55K | -239.13%-32K | -3K | -350.00%-9K | 23K | -2K |
| Other non- operating income (expenses) | -766.67%-26K | -511.11%-55K | -239.13%-32K | ---3K | -350.00%-9K | --23K | ---2K |
| Income before tax | -139.55%-26.69M | -108.93%-60.37M | -143.26%-20.67M | -11.14M | -9.65%-28.89M | -8.5M | -26.35M |
| Income tax | |||||||
| Net income | -139.55%-26.69M | -108.93%-60.37M | -143.26%-20.67M | -11.14M | -9.65%-28.89M | -8.5M | -26.35M |
| Net income continuous Operations | -139.55%-26.69M | -108.93%-60.37M | -143.26%-20.67M | ---11.14M | -9.65%-28.89M | ---8.5M | ---26.35M |
| Minority interest income | |||||||
| Net income attributable to the parent company | -139.55%-26.69M | -108.93%-60.37M | -143.26%-20.67M | -11.14M | -9.65%-28.89M | -8.5M | -26.35M |
| Preferred stock dividends | |||||||
| Other preferred stock dividends | |||||||
| Net income attributable to common stockholders | -139.55%-26.69M | -108.93%-60.37M | -143.26%-20.67M | -11.14M | -9.65%-28.89M | -8.5M | -26.35M |
| Basic earnings per share | -159.36%-1.12 | -32.06%-1.4787 | -53.76%-0.5063 | -0.4318 | -9.65%-1.1197 | -0.3293 | -1.0212 |
| Diluted earnings per share | -159.36%-1.12 | -32.06%-1.4787 | -53.76%-0.5063 | -0.4318 | -9.65%-1.1197 | -0.3293 | -1.0212 |
| Dividend per share | |||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
